FDA Revises Labels on GLP-1 Drugs with New Cardiovascular Risk Reduction Information

FDA Revises Labels on GLP-1 Drugs with New Cardiovascular Risk Reduction Information

The U.S. Food and Drug Administration revised prescribing information for three GLP-1 receptor agonists to include results from dedicated cardiovascular outcomes trials. The September 28, 2023 update adds data on major adverse cardiovascular events for liraglutide, semaglutide, and dulaglutide in adults with type 2 diabetes who had established cardiovascular disease or elevated cardiovascular risk. The changes translate findings from the LEADER, SUSTAIN-6, and REWIND trials directly into FDA-approved product labels.

These revisions make trial-specific hazard ratios and confidence intervals available within regulatory documents that clinicians routinely consult.

FDA Requires Inclusion of CVOT Results

The FDA labeling update scope requires inclusion of cardiovascular outcomes trial results showing MACE reduction in labeling for liraglutide, semaglutide, and dulaglutide. [1] The agency’s action follows completion of large-scale trials that met regulatory thresholds for demonstrating statistically significant reductions in major adverse cardiovascular events, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

LEADER Trial Data for Liraglutide

The LEADER trial reported that liraglutide reduced 3-point MACE by 13% (HR 0.87; 95% CI 0.78-0.97) compared with placebo. [2] Conducted in more than 9,000 adults with type 2 diabetes and high cardiovascular risk, the study provides the peer-reviewed source data now reflected in the updated label.

SUSTAIN-6 Trial Data for Semaglutide

The SUSTAIN-6 trial found that semaglutide reduced 3-point MACE by 26% (HR 0.74; 95% CI 0.58-0.95) versus placebo. [3] This placebo-controlled study enrolled patients with type 2 diabetes at high cardiovascular risk and supplies the primary evidence cited in the revised semaglutide labeling.

REWIND Trial Data for Dulaglutide

The REWIND trial supplied the cardiovascular outcomes data added to dulaglutide labeling. [4] The study examined dulaglutide in a population that included individuals with type 2 diabetes and either established cardiovascular disease or multiple risk factors.

What this means

The labeling changes consolidate trial-specific results on MACE reductions, hazard ratios, confidence intervals, and studied populations into the official FDA-approved documents. This gives regulators-vetted cardiovascular findings a standardized place alongside dosing, safety, and indication information. The updates apply only to the three agents with completed trials that satisfied regulatory criteria for cardiovascular data and do not characterize cardiovascular benefit as a class-wide property of all GLP-1 receptor agonists.

Limitations

The update applies only to agents with completed dedicated CVOTs meeting regulatory thresholds; it does not extend to all GLP-1 receptor agonists. Trial data reflect specific populations with established CVD or high risk and the trial durations used; real-world long-term outcomes may differ. Cardiovascular benefit is not considered a class effect. The labeling changes do not alter boxed warnings or core safety information.